ViroPharma's Buccolam®▼ (Midazolam, Oromucosal Solution) now Available in Wales for Treatment of Prolonged Acute Convulsive Seizures

ViroPharma's Buccolam®▼ (Midazolam, Oromucosal Solution) now Available in Wales for Treatment of Prolonged Acute Convulsive Seizures PR Newswire MAIDENHEAD, England, June 21, 2012 MAIDENHEAD, England, June 21, 2012 /PRNewswire/ -- - First Paediatric Licensed Treatment Option for Children and Adolescents Under 18 Now Available for Use by NHS Wales - - AWMSG Take Rare Decision to Advise Prescription by Brand Name - Clinicians and carers of children and adolescents from 3 months to <18 years suffering from prolonged, acute, convulsive ®seizures now have access to Buccolam (midazolam, oromucosal solution) through NHS Wales, following the approval [1]from the All Wales Medicines Strategy Group (AWMSG). Buccolam will be marketed in Wales by ViroPharma Limited, a wholly-owned subsidiary of ViroPharma Incorporated (NASDAQ: VPHM). The full advice reads as follows: Midazolam (BUCCOLAM®) is recommended as an option for use within NHS Wales for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to <18 years). For infants between 3–6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. Midazolam (BUCCOLAM®) should be prescribed by brand name to reduce the risk of medication errors. Buccolam has anti-convulsant, sedative, and muscle-relaxant effects and is effective when given by the oromucosal route, i.e.